scholarly journals Meta-Analysis Comparing Steroids and Diuretics in the Treatment of Acute Low-Tone Sensorineural Hearing Loss

2019 ◽  
pp. 014556131986961
Author(s):  
Yueying Zhu ◽  
Guangqi Li ◽  
Huiwen Zhuang ◽  
Zijun Yang ◽  
JinCangjian Sun ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Recovery Rate ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Evaluation Criteria ◽  
Sensorineural Hearing ◽  
Fixed Effects Model ◽  
Significant Difference ◽  
Low Tone

Objective: Our objective was to perform a meta-analysis to compare the effectiveness of steroids and diuretics in the treatment of acute low-tone sensorineural hearing loss (ALHL). Methods: PubMed, Google Scholar, and Sci databases were searched for randomized controlled trials (RCTs) examining the treatment of ALHL with steroids and diuretics. The Cochrane Reviewer’s Handbook 5.0 evaluation criteria were used to evaluate the quality of the included RCTs. Meta-analysis was performed using Revman 5.3 software to compare the recovery rate of low-tone hearing levels between patients treated with steroids and diuretics. Results: A total of 3 RCTs were included. There was no heterogeneity between the 3 studies (χ2 = 2.61, P = .27, I 2 = 23%); thus, a fixed-effects model of analysis was used. Meta-analysis showed there was no significant difference in the recovery rate of patients treated with steroids and those treated with diuretics (odds ratio = 1.48, 95% confidence interval: 0.64-3.40, P = .36). Conclusion: Steroids and diuretics are equally effective for the treatment of ALHL.

scholarly journals Relationship between platelet parameters and sudden sensorineural hearing loss: a systematic review and meta-analysis

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Shuaifei Ji ◽  
Xuemin Chen ◽  
Heng Shi ◽  
Babo Zhang ◽  
Shun Yao ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Meta Analysis ◽  
Geographical Area ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Distribution Width ◽  
Eastern Country ◽  
Standard Mean Difference ◽  
Significant Difference

Recent years, the discussion about whether platelets participant in the development of sudden sensorineural hearing loss (SSHL) continues and many studies on the relationship between them have come to our attention. Some studies believe that platelet parameters have significantly changed in patients with SSHL, while some not, controversially. Therefore, to investigate the association between platelet parameters, including mean platelet volume (MPV), platelet distribution width (PDW) and platelet count (PLT), and SSHL, expecting to resolve controversy and provide clinical evidence for diagnosis and monitoring of SSHL. Basic methods: Literature was retrieved searching electronic databases (PubMed, Embase, Cochrane, and Scopus) and searching references of related articles by hand. A total of 18 case–control studies involving 1837/1734 subjects (SSHL/control) were included. Meta-analysis showed there was no difference between the patients who suffered SSHL and healthy controls in MPV level [standard mean difference (SMD) (95% confidence interval (CI)) = 0.16 (−0.07, 0.40), I2 = 80%, P<0.00001] and PLT [SMD (95% CI) = −0.03(−0.18, 0.12), I2 = 73%, P<0.00001]. While PDW exhibited significant difference [SMD (95% CI) = 0.85 (0.20, 1.49), I2 = 93%, P<0.00001]. Subgroup analysis about geographical area suggested PLT have obvious evidence for SSHL in Eastern country [SMD (95% CI) = 0.23 (0.14, 0.33), I2 = 0%, P=0.81]. Our study did not support a correlation between MPV and SSHL, while PLT may have clinical significance for SSHL in Eastern country. With insufficient data to explore the resource of heterogeneity for PDW, there is no decisive conclusion reached.

Idiopathic Sudden Sensorineural Hearing Loss in Children: A Systematic Review and Meta-analysis

2020 ◽  
pp. 019459982097657
Author(s):  
Leonardo Franz ◽  
Chiara Gallo ◽  
Gino Marioni ◽  
Cosimo de Filippis ◽  
Andrea Lovato
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Case Reports ◽  
Meta Analysis ◽  
Treatment Options ◽  
Case Series ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Systemic Steroid ◽  
Significant Difference

Objective Idiopathic sudden sensorineural hearing loss (ISSNHL) is uncommon in children, and its treatment and outcome are debated. We aimed to critically review evidence in the literature about treatment options and functional outcomes of pediatric ISSNHL. Additionally, we performed a meta-analysis of the results of combined systemic-intratympanic steroid therapy versus solely systemic treatment. Data Sources A search was run in the PubMed, Scopus, and Google Scholar databases. Review Methods Included articles were original ISSNHL case series, written in English, with a population age ranging from 2 to 19 years. Other study types (single case reports, editorials, and reviews) and case series with known etiology of sudden hearing loss were excluded. Descriptive data of patients, treatments, outcomes, and possible prognostic factors were extracted and recorded for every included study. Results Twelve articles (7 cohort and 5 case-control studies) met all the selection criteria. Based on only the studies that provided sufficient data about clinical outcome, the pooled overall recovery rate was 67.91% (95% CI, 58.34%-77.48%). No studies showed a significant difference between systemic steroid and combined systemic-intratympanic steroid. The pooled odds ratio for combined systemic-intratympanic steroid versus systemic steroid alone was 0.90 (95% CI, 0.36-2.27) based on a random effects model, ruling out any significant difference between these treatment options. Conclusions The results of our meta-analysis did not support combination therapy more than systemic steroid alone. Further prospective clinical trials are necessary to establish evidence-based therapies.

scholarly journals Sudden sensorineural hearing loss in patients with vestibular schwannoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Koichiro Wasano ◽  
Naoki Oishi ◽  
Masaru Noguchi ◽  
Ko Hentona ◽  
Seiichi Shinden ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Clinical Features ◽  
Vestibular Schwannoma ◽  
Recovery Rate ◽  
Treatment Plan ◽  
Full Range ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Recurrence Time

AbstractClinical features of sudden sensorineural hearing loss (SSNHL) associated with vestibular schwannoma (VS) are not fully understood. Determining a treatment plan and explaining it to patients requires clinicians to clearly understand the clinical features related to the tumor, including SSNHL. To identify the full range of clinical features of VS-associated SSNHL, especially recovery of hearing following multiple episodes of SSNHL and what factors predict recovery and recurrence. A multicenter retrospective chart review was conducted in seven tertiary care hospitals between April 1, 2011, and March 31, 2020. We collected and analyzed dose of administered steroid, pure-tone audiometry results, and brain MRIs of patients diagnosed with VS-associated SSNHL. Seventy-seven patients were included. They experienced 109 episodes of audiogram-confirmed SSNHL. The highest proportion of complete recoveries occurred in patients with U-shaped audiograms. The recovery rates for the first, second, and third and subsequent episodes of SSNHL were 53.5%, 28.0%, and 9.1%, respectively. Recovery rate decreased significantly with increasing number of SSNHL episodes (P =0 .0011; Cochran-Armitage test). After the first episode of SSNHL, the recurrence-free rate was 69.9% over 1 year and 57.7% over 2 years; the median recurrence time was 32 months. Logarithmic approximation revealed that there is a 25% probability that SSNHL would recur within a year. SSNHL in patients with VS is likely to recur within one year in 25% of cases. Also, recovery rate decreases as a patient experiences increasing episodes of SSNHL.

Otologics Fully Implantable Hearing Device Phase II Results

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P57-P57
Author(s):  
Drew M Horlbeck ◽  
Herman A Jenkins ◽  
Ben J Balough ◽  
Michael E Hoffer
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Phase Ii ◽  
Hearing Aids ◽  
Repeated Measures ◽  
Pure Tone ◽  
Sound Field ◽  
Sensorineural Hearing ◽  
Significant Difference ◽  
Hearing Device

Objective The efficacy of the Otologics Fully Implantable Hearing Device (MET) was assessed in adult patients with bilateral moderate to severe sensorineural hearing loss. Methods Surgical insertion of this totally implanted system was identical to the Phase I study. A repeated-measures within-subjects design assessed aided sound field thresholds and speech performances with the subject's own, appropriately fit, walk-in hearing aid(s) and the Otologics Fully Implantable Hearing Device. Results Six- and 12-month Phase II data will be presented. Ten patients were implanted and activated as part Phase II clinical trial. Three patients were lost to long term follow-up due to two coil failures and one ossicular abnormality preventing proper device placement. No significant differences between preoperative (AC = 59 dB, BC = 55 dB) and postoperative (AC = 61 dB, BC = 54 dB) unaided pure tone averages were noted (p < 0.05). Pure tone average implant aided thresholds (41 dB) were equivalent to that of walk-in-aided (37 dB) condition with no significant difference (p < 0.05) between patients’ walk-in-aided individual frequency thresholds and implant-aided thresholds. Word recognition scores and hearing in noise scores were similar between the walk-in-aided and for the implant-aided condition. Patient benefit scales will be presented at all end points. Conclusions Results of the Otologics MET Fully Implantable Hearing Device Phase II trial provide evidence that this fully implantable device is a viable alternative to currently available hearing aids in patients with sensorineural hearing loss.

Acute Low-Tone Sensorineural Hearing Loss Without Vertigo

1994 ◽  
Vol 120 (5) ◽  
pp. 532-535 ◽  
Author(s):  
T. Yamasoba ◽  
S. Kikuchi ◽  
M. Sugasawa ◽  
M. Yagi ◽  
T. Harada
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Low Tone

scholarly journals Comparison of sensorineural hearing loss characteristics in different hemodialysis vascular accesses

2020 ◽  
Author(s):  
Behieh Kohansall ◽  
Nasser Saeedi ◽  
Moeinoddin Hossein Beigi ◽  
Azam Moslemi ◽  
Akram Valizadeh
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Vascular Access ◽  
Demographic Data ◽  
Life Quality ◽  
Cross Sectional Study ◽  
Sensorineural Hearing ◽  
Moderate Degree ◽  
Cross Sectional ◽  
Significant Difference

Background and Aim: Sensorineural hearing loss (SNHL) is one of the complications in hemodialysis patients. Vascular access (VA) represents a lifeline for these patients affecting their life quality and clinical outcomes. Arterio­venous fistula is the gold standard of VAs with minor complications and better hemodialysis adequacy. There is no study investigating hearing differences in hemodialysis VAs. Hence, this study aimed to compare SNHL characteristics amongst hemodialysis VAs. Methods: This cross-sectional study conducted on 64 patients aged 18−60 years received regular hemodialysis in 2019. Demographic data and comorbid conditions were recorded based on patients’ case records and electronic databases. After a physical examination, otoscopy, tympa­nometry, and conventional audiometry, patients were divided into fistula (n = 26), permanent catheter (n = 36), and temporary catheter (n = 2) groups according to vascular access type. Results: Prevalence rate of SNHL was 63.89%, 50% and 50% in the permanent catheter, fistula and temporary catheter groups, respectively. Most patients had mild sloping-SNHL in the per­manent catheter and fistula groups as against moderate degree in the other group. There was no significant difference in hearing thresholds, deg­ree and audiogram shape among VA groups. No significant relation was found between age, sex, hemodialysis duration and disease duration with hearing loss in all groups (p > 0.05). Conclusion: More patients had SNHL in per­manent catheter group. Vascular access types, longer duration of hemodialysis and disease dur­ation do not seem to be associated with SNHL. However, further investigation is needed to cla­rify the relationship. Keywords: Sensorineural hearing loss; vascular access; chronic renal failure; hemodialysis

Effectiveness and Safety Studies of Omalizumab in Children and Adolescents With Moderate-To-Severe Asthma

2021 ◽  
pp. 089719002110382
Author(s):  
Lu Cheng ◽  
Tianrui Yang ◽  
Xiang Ma ◽  
Yuling Han ◽  
Yongtai Wang
Keyword(s):  
Children And Adolescents ◽  
Allergic Asthma ◽  
Severe Asthma ◽  
Fixed Effects ◽  
Vital Capacity ◽  
Immunoglobulin E ◽  
Meta Analysis ◽  
Fixed Effects Model ◽  
Significant Difference ◽  
Severe Allergic Asthma

Background Omalizumab is currently approved for the treatment of moderate-to-severe allergic asthma in patients 6 years and older. Objective To assess the effectiveness and safety of subcutaneous omalizumab as an add-on therapy option for moderate–severe allergic asthma in patients aged 6—20 years old. Methods The studies published from July, 1970 to May, 2021 were searched from the electronic databases which followed keywords: (“anti-IgE” OR “anti-immunoglobulin E” OR “anti-IgE antibody” OR “omalizumab” OR “rhuMAb-E25” OR “Xolair”) AND “asthma” AND (“child” OR “children” OR “adolescents” OR “youth” OR “teenager” OR “kids” OR “pediatric”). Thirteen studies were pooled to determine the effectiveness and safety of omalizumab. Efficacy endpoints were evaluated using a fixed-effects model or a random-effects model depending on heterogeneity. Safety endpoints were evaluated by odds ratio. Results Thirteen studies were included. In this meta-analysis, our results showed that fractional exhaled nitric oxide and asthma control test scores were significantly improved with omalizumab treatment. Serum immunoglobulin E was also decreased in children with moderate-to-severe asthma after treatment with omalizumab. The analysis found that there was no significant difference between pre-and post-treatment in forced expiratory volume in one second/ forced vital capacity ratio, forced expiratory flow between 25 and 75% of vital capacity, or FEV1. Overall, more adverse events occurred with omalizumab compared to placebo. However, the degree was mild to moderate. Conclusion This meta-analysis indicates that omalizumab is safe and effective to treat children and adolescents with moderate-to-severe asthma.

Sign in / Sign up

Export Citation Format

Share Document